218 related articles for article (PubMed ID: 32545874)
21. Amino Acid Uptake Measured by [
Prudner BC; Sun F; Kremer JC; Xu J; Huang C; Sai KKS; Morgan Z; Leeds H; McConathy J; Van Tine BA
Theranostics; 2018; 8(8):2107-2116. PubMed ID: 29721066
[No Abstract] [Full Text] [Related]
22. Regression of hepatocellular cancer in a patient treated with arginine deiminase.
Curley SA; Bomalaski JS; Ensor CM; Holtsberg FW; Clark MA
Hepatogastroenterology; 2003; 50(53):1214-6. PubMed ID: 14571701
[TBL] [Abstract][Full Text] [Related]
23. Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase.
Kelly MP; Jungbluth AA; Wu BW; Bomalaski J; Old LJ; Ritter G
Br J Cancer; 2012 Jan; 106(2):324-32. PubMed ID: 22134507
[TBL] [Abstract][Full Text] [Related]
24. Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells.
Yeh TH; Chen YR; Chen SY; Shen WC; Ann DK; Zaro JL; Shen LJ
Mol Pharm; 2016 Jan; 13(1):262-71. PubMed ID: 26642391
[TBL] [Abstract][Full Text] [Related]
25. A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients.
Tsai HJ; Jiang SS; Hung WC; Borthakur G; Lin SF; Pemmaraju N; Jabbour E; Bomalaski JS; Chen YP; Hsiao HH; Wang MC; Kuo CY; Chang H; Yeh SP; Cortes J; Chen LT; Chen TY
Sci Rep; 2017 Sep; 7(1):11253. PubMed ID: 28900115
[TBL] [Abstract][Full Text] [Related]
26. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
Ensor CM; Holtsberg FW; Bomalaski JS; Clark MA
Cancer Res; 2002 Oct; 62(19):5443-50. PubMed ID: 12359751
[TBL] [Abstract][Full Text] [Related]
27. Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase.
Yoon CY; Shim YJ; Kim EH; Lee JH; Won NH; Kim JH; Park IS; Yoon DK; Min BH
Int J Cancer; 2007 Feb; 120(4):897-905. PubMed ID: 17096330
[TBL] [Abstract][Full Text] [Related]
28. Arginine-lowering enzymes against cancer: a technocommercial analysis through patent landscape.
Dhankhar R; Gulati P; Kumar S; Kapoor RK
Expert Opin Ther Pat; 2018 Aug; 28(8):603-614. PubMed ID: 30092168
[TBL] [Abstract][Full Text] [Related]
29. Sensitivity of Colorectal Cancer to Arginine Deprivation Therapy is Shaped by Differential Expression of Urea Cycle Enzymes.
Alexandrou C; Al-Aqbi SS; Higgins JA; Boyle W; Karmokar A; Andreadi C; Luo JL; Moore DA; Viskaduraki M; Blades M; Murray GI; Howells LM; Thomas A; Brown K; Cheng PN; Rufini A
Sci Rep; 2018 Aug; 8(1):12096. PubMed ID: 30108309
[TBL] [Abstract][Full Text] [Related]
30. The Citrulline Recycling Pathway Sustains Cardiovascular Function in Arginine-Depleted Healthy Mice, but Cannot Sustain Nitric Oxide Production during Endotoxin Challenge.
Yuan Y; Mohammad MA; Betancourt A; Didelija IC; Yallampalli C; Marini JC
J Nutr; 2018 Jun; 148(6):844-850. PubMed ID: 29878271
[TBL] [Abstract][Full Text] [Related]
31. Engineering an arginine catabolizing bioconjugate: Biochemical and pharmacological characterization of PEGylated derivatives of arginine deiminase from Mycoplasma arthritidis.
Wang M; Basu A; Palm T; Hua J; Youngster S; Hwang L; Liu HC; Li X; Peng P; Zhang Y; Zhao H; Zhang Z; Longley C; Mehlig M; Borowski V; Sai P; Viswanathan M; Jang E; Petti G; Liu S; Yang K; Filpula D
Bioconjug Chem; 2006; 17(6):1447-59. PubMed ID: 17105223
[TBL] [Abstract][Full Text] [Related]
32. A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Phillips MM; Pavlyk I; Allen M; Ghazaly E; Cutts R; Carpentier J; Berry JS; Nattress C; Feng S; Hallden G; Chelala C; Bomalaski J; Steele J; Sheaff M; Balkwill F; Szlosarek PW
Pharmacol Rep; 2023 Jun; 75(3):570-584. PubMed ID: 37010783
[TBL] [Abstract][Full Text] [Related]
33. Pegylated arginine deiminase depletes plasma arginine but maintains tissue arginine availability in young pigs.
Mohammad MA; Didelija IC; Stoll B; Nguyen TC; Marini JC
Am J Physiol Endocrinol Metab; 2021 Mar; 320(3):E641-E652. PubMed ID: 33427052
[TBL] [Abstract][Full Text] [Related]
34. The role of arginine and the modified arginine deiminase enzyme ADI-PEG 20 in cancer therapy with special emphasis on Phase I/II clinical trials.
Synakiewicz A; Stachowicz-Stencel T; Adamkiewicz-Drozynska E
Expert Opin Investig Drugs; 2014 Nov; 23(11):1517-29. PubMed ID: 24965808
[TBL] [Abstract][Full Text] [Related]
35. Purification, immobilization, and biochemical characterization of l-arginine deiminase from thermophilic Aspergillus fumigatus KJ434941: anticancer activity in vitro.
El-Sayed AS; Hassan MN; Nada HM
Biotechnol Prog; 2015; 31(2):396-405. PubMed ID: 25582958
[TBL] [Abstract][Full Text] [Related]
36. Intracellular expression of arginine deiminase activates the mitochondrial apoptosis pathway by inhibiting cytosolic ferritin and inducing chromatin autophagy.
Feng Q; Bian X; Liu X; Wang Y; Zhou H; Ma X; Quan C; Yao Y; Zheng Z
BMC Cancer; 2020 Jul; 20(1):665. PubMed ID: 32677906
[TBL] [Abstract][Full Text] [Related]
37. Rational surface engineering of an arginine deiminase (an antitumor enzyme) for increased PEGylation efficiency.
Cheng F; Yang J; Schwaneberg U; Zhu L
Biotechnol Bioeng; 2019 Sep; 116(9):2156-2166. PubMed ID: 31062871
[TBL] [Abstract][Full Text] [Related]
38. Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells.
Tsai WB; Aiba I; Long Y; Lin HK; Feun L; Savaraj N; Kuo MT
Cancer Res; 2012 May; 72(10):2622-33. PubMed ID: 22461507
[TBL] [Abstract][Full Text] [Related]
39. Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy.
Stone E; Chantranupong L; Gonzalez C; O'Neal J; Rani M; VanDenBerg C; Georgiou G
J Control Release; 2012 Feb; 158(1):171-9. PubMed ID: 22001609
[TBL] [Abstract][Full Text] [Related]
40. Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction.
Long Y; Tsai WB; Wangpaichitr M; Tsukamoto T; Savaraj N; Feun LG; Kuo MT
Mol Cancer Ther; 2013 Nov; 12(11):2581-90. PubMed ID: 23979920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
